Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPLY: Prophylactic Rituximab in EBV-negative Kidney Transplant Recipients
2024-515075-36-00Phase 4Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of rituximab in Post-Transplant Lymphoproliferative Disorder (PTLD) and Epstein-Barr virus infection (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: 1-year incidence of composite EBV outcome. Planned start Jul 2024; status: authorised.
02
Drugs
rituximab
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)Epstein-Barr virus infection
Beyond the preview
Go deeper on 2024-515075-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515075-36-00.